Back to top
more

Novavax (NVAX)

(Real Time Quote from BATS)

$8.36 USD

8.36
3,944,166

-0.20 (-2.34%)

Updated Sep 17, 2025 03:44 PM ET

After-Market: $8.39 +0.03 (0.36%) 4:08 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.64%
2Buy17.83%
3Hold9.69%
4Sell5.29%
5Strong Sell2.54%
S&P50011.29%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value C Growth D Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 40% (97 out of 245)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Neena Mishra headshot

Can Biotech ETFs Continue to Soar in 2020?

by Neena Mishra

We discuss coronavirus, cancer drugs, gene therapies, crispr and related biotech stocks & ETFs.

Zacks Equity Research

Novavax (NVAX) Stock Sinks As Market Gains: What You Should Know

by Zacks Equity Research

In the latest trading session, Novavax (NVAX) closed at $6.97, marking a -0.57% move from the previous day.

Zacks Equity Research

Novavax, Inc. (NVAX) Shares March Higher, Can It Continue?

by Zacks Equity Research

As of late, it has definitely been a great time to be an investor Novavax, Inc. (NVAX).

Kevin Cook headshot

Coronavirus: How Fast to 100,000 Infected?

by Kevin Cook

The current geometric rate of transmission implies that over 100,000 people could be infected by early February.

Kevin Cook headshot

Coronavirus: Epidemic or Pandemic?

by Kevin Cook

The current geometric rate of transmission implies that over 100,000 people could be infected by early February.

Zacks Equity Research

Has Novavax (NVAX) Outpaced Other Medical Stocks This Year?

by Zacks Equity Research

Is (NVAX) Outperforming Other Medical Stocks This Year?

Indrajit Bandyopadhyay headshot

CEPI Grant, Government Aid Drive Coronavirus Focused Biotechs

by Indrajit Bandyopadhyay

Several public and private organizations are coming forward to develop vaccines for the new coronavirus by funding developmental programs.

Zacks Equity Research

3 Biotech Stocks Likely to Gain as Coronavirus Spreads

by Zacks Equity Research

Here we discuss three biotech stocks, which are likely to benefit in case there is an outbreak of coronavirus infection in China.

Zacks Equity Research

The Zacks Analyst Blog Highlights: Novavax, NanoViricides, Aethlon Medical and Oncolytics Biotech

by Zacks Equity Research

The Zacks Analyst Blog Highlights: Novavax, NanoViricides, Aethlon Medical and Oncolytics Biotech

Zacks Equity Research

Company News for Jan 22, 2020

by Zacks Equity Research

Companies in the news are: NVAX, UBER, CSS, VIVE

Zacks Equity Research

Options Traders Expect Huge Moves in Novavax (NVAX) Stock

by Zacks Equity Research

Investors need to pay close attention to Novavax (NVAX) stock based on the movements in the options market lately.

Tirthankar Chakraborty headshot

Coronavirus Infects Wall Street: Stocks to Gain & Lose

by Tirthankar Chakraborty

While travel-related stocks were hit hard on concerns over coronavirus, experimental vaccine companies rallied.

Zacks Equity Research

Novavax Rises on Fast Track Designation to Influenza Vaccine

by Zacks Equity Research

The FDA bestows a Fast Track Designation on Novavax's (NVAX) influenza vaccine candidate NanoFlu for adults aged 65 years and older. Shares rally.

Zacks Equity Research

Options Traders Expect Huge Moves in Novavax (NVAX) Stock

by Zacks Equity Research

Investors need to pay close attention to Novavax (NVAX) stock based on the movements in the options market lately.

Zacks Equity Research

Will Novavax (NVAX) Report Negative Q3 Earnings? What You Should Know

by Zacks Equity Research

Novavax (NVAX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Equity Research

Novavax Begins Phase III Study on Influenza Vaccine Candidate

by Zacks Equity Research

Novavax (NVAX) starts a pivotal late-stage study on its pipeline candidate NanoFlu influenza vaccine in senior patients. Shares up.

Zacks Equity Research

Zacks.com featured highlights include: Odonate Therapeutics, Novavax, Beazer Homes USA and NVIDIA

by Zacks Equity Research

Zacks.com featured highlights include: Odonate Therapeutics, Novavax, Beazer Homes USA and NVIDIA

Tirthankar Chakraborty headshot

4 of the Best Stocks With Solid Earnings Acceleration

by Tirthankar Chakraborty

Studies have shown that a majority of successful stocks see acceleration in earnings before an uptick in the stock price.

Zacks Equity Research

Are Options Traders Betting on a Big Move in Novavax (NVAX) Stock?

by Zacks Equity Research

Investors need to pay close attention to Novavax (NVAX) stock based on the movements in the options market lately.

Zacks Equity Research

Zacks.com featured highlights include: Novavax, The Cooper Companies, Veeco Instruments and Maxar Technologies

by Zacks Equity Research

Zacks.com featured highlights include: Novavax, The Cooper Companies, Veeco Instruments and Maxar Technologies

Tirthankar Chakraborty headshot

4 Stocks That Boast Superb Earnings Acceleration

by Tirthankar Chakraborty

Studies have shown that a majority of stocks had seen acceleration in earnings before a rally in stock price.

Zacks Equity Research

Novavax, Inc. (NVAX) Shares March Higher, Can It Continue?

by Zacks Equity Research

As of late, it has definitely been a great time to be an investor in Novavax, Inc. (NVAX).

Zacks Equity Research

Implied Volatility Surging for Novavax (NVAX) Stock Options

by Zacks Equity Research

Investors need to pay close attention to Novavax (NVAX) stock based on the movements in the options market lately.

Zacks Equity Research

Novavax (NVAX) Reports Q2 Loss, Misses Revenue Estimates

by Zacks Equity Research

Novavax (NVAX) delivered earnings and revenue surprises of -4.97% and -4.98%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Novavax (NVAX) Seeks Accelerated Approval Pathway for NanoFlu

by Zacks Equity Research

Novavax (NVAX) seeks to use accelerated approval pathway for its influenza vaccine candidate, NanoFlu, in the United States.